Indian pharma companies like Dr Reddy’s, Zydus, Cipla, and Sun can sustain low double-digit EPS growth over the medium term.
Cipla's US sales are expected to be adversely impacted by price erosion and supply disruptions for tumor drug Lanreotide, ...
Stay informed with the Cipla Stock Liveblog, your comprehensive resource for real-time updates and in-depth analysis of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback